VKTX Viking Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1607678 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-164.2%
TTM EPS YoY-155.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.4%
ROA-73.1%
ROIC (approx.)-195.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets39.8%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-19.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $166.80M | $115.75M | $150.15M | $153.46M | $89.95M | $60.15M | $41.39M | $30.99M |
| SG&A expense | $20.31M | $16.84M | $13.97M | $11.28M | $8.61M | $14.42M | $14.08M | $15.25M |
| Operating income | -$187.11M | -$132.60M | -$164.12M | -$164.74M | -$98.56M | -$74.57M | -$55.47M | -$46.24M |
| Interest expense | $88,000 | — | — | — | $0 | — | — | — |
| Net income | -$183.19M | -$128.02M | -$158.32M | -$157.66M | -$90.79M | -$65.56M | -$45.63M | -$35.42M |
| EPS (basic) | -1.55 | -1.10 | -1.37 | — | -0.81 | -0.58 | -0.41 | — |
| EPS (diluted) | -1.55 | -1.10 | -1.37 | — | -0.81 | -0.58 | -0.41 | — |
| Weighted avg. shares (diluted) | 118.05M | 116.26M | 115.57M | — | 112.32M | 112.13M | 112.07M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $677.61M | $125.75M | $118.12M | $165.81M | $100.38M | $33.88M | $37.94M | $26.68M |
| Short-term investments | $282.20M | $375.91M | $484.85M | $539.93M | $614.19M | $773.84M | $813.92M | $875.94M |
| Current assets | $973.00M | $517.56M | $608.21M | $715.60M | $738.70M | $827.02M | $866.02M | $907.22M |
| Total assets | $977.17M | $521.90M | $608.24M | $715.73M | $739.41M | $827.85M | $866.99M | $908.32M |
| Current liabilities | $133.90M | $109.66M | $106.33M | $76.67M | $26.07M | $31.98M | $19.57M | $27.41M |
| Total liabilities | $388.57M | $113.58M | $106.33M | $76.67M | $26.39M | $32.39M | $20.07M | $28.04M |
| Shareholders' equity | $588.60M | $408.32M | $501.92M | $639.06M | $713.03M | $795.46M | $846.92M | $880.28M |
| Shares outstanding | 127.52M | 116.65M | 115.89M | 114.79M | 112.45M | 112.33M | 112.29M | 111.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$138.19M | -$125.17M | -$113.98M | -$85.29M | -$94.00M | -$47.06M | -$52.33M | -$31.18M |
| Investing cash flow | $92.52M | $109.43M | $54.19M | $75.61M | $160.03M | $42.51M | $63.24M | $6.58M |
| Financing cash flow | $597.55M | $23.59M | $12.08M | $75.10M | $480,000 | $507,000 | $349,000 | $1.00M |
| Stock-based compensation | $17.89M | $11.13M | $10.34M | $8.59M | $7.34M | $13.55M | $11.35M | $5.67M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.